Exelixis shares are trading lower after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating cabozantinib in advanced neuroendocrine tumors.
Portfolio Pulse from Benzinga Newsdesk
Exelixis announced detailed results from its Phase 3 CABINET pivotal trial evaluating cabozantinib in advanced neuroendocrine tumors, causing its shares to trade lower.
October 23, 2023 | 6:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Exelixis shares are trading lower after the company announced results from its Phase 3 trial of cabozantinib.
The announcement of the Phase 3 trial results has directly impacted Exelixis' stock price, causing it to trade lower. This suggests that the market may have had negative perceptions of the results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100